TORRENT PHARMACEUTICALS LTD. - 500420 - Clarification sought from Torrent Pharmaceuticals Ltd
The Exchange has sought clarification from Torrent Pharmaceuticals Ltd with respect to news article appearing on https://www.moneycontrol.com/ December 27, 2021 titled "Torrent Pharma recalls over 27,000 bottles of blood pressure lowering drug in US".The reply is awaited. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Updated Press Release - Torrent Pharma to launch Molnupiravir under the brand name Molnutor(r) in India TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release - Torrent Pharma introduces Molnupiravir under the brand name Molnutor(r) in India TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Pursuant to Regulation 30 read with Schedule III of the Listing Regulations, we would like to inform that the Company has issued Corporate Guarantee to MUFG Bank Ltd., ('bank') for an amount upto USD 80 Million in respect of the credit facility availed / to be availed by Torrent Pharma Inc. (TPI), USA, a wholly owned subsidiary of the Company.
USFDA inspection of co's US plant completed successfully: Torrent Pharma
Torrent Pharmaceuticals Ltd on Thursday said its manufacturing facility at Levittown, Pennsylvania in the US has successfully completed inspection by the USFDA. The plant was inspected by USFDA (United States Food and Drug Administration) between December 6 and December 15, 2021. At the end of the inspection, no 'Form 483' was issued, the company said in a regulatory filing. As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when an investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. "It is a positive development for the company and is a reflection of our commitment to consistency in quality and compliance with regulatory standards," Torrent Pharmaceuticals said. According to information available on the company's website, the Levittown manufacturing facility is a part of Torrent Pharma's acquisition of Bio-Pharm, Inc (BPI) in 2018. It has... TORRENT PHARMACEUTICALS LTD. - 500420 - USFDA Inspection At Torrent'S Manufacturing Facility At Levittown, Pennsylvania, USA
This is to inform that our Levittown, Pennsylvania, USA manufacturing facility was inspected by USFDA (United States Food and Drug Administration) between 6th December 2021 and 15th December 2021. At the end of the inspection, No Form 483 was issued. It is a positive development for the Company and is a reflection of our commitment to consistency in quality and compliance with regulatory standards. Kindly take note of the same. TORRENT PHARMACEUTICALS LTD. - 500420 - Partial Redemption Of Non-Convertible Debentures
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Secured Redeemable Non-Convertible Debentures (NCDs) of Rs 142.86 crores (Rupees One Hundred Forty Two Crores Eighty Six Lakhs) out of the total NCDs of Rs 1000 crores (Rupees One Thousand Crores) issued under ISIN: INE685A07082 has been redeemed and repaid by the Company on 14-Dec-21. TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Issue of Duplicate Share Certificate TORRENT PHARMACEUTICALS LTD. - 500420 - Redemption Of Non-Convertible Debentures
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Secured Redeemable Non-Convertible Debentures (NCDs) of Rs 150 crores (Rupees One Hundred Fifty Crores) out of the total NCDs of Rs 500 crores (Rupees Five Hundred Crores) issued under ISIN: INE685A07066 has been redeemed and repaid by the Company on 13-Dec-21.
Buy Torrent Pharmaceuticals: target of Rs 3620: Sharekhan
Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 3620 in its research report dated December 09, 2021.